Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics ...
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...